Navigation Links
Insmed to Request Hearing Before NASDAQ Panel to Review NASDAQ Staff Determination
Date:6/20/2008

RICHMOND, Va., June 20 /PRNewswire-FirstCall/ -- Insmed Inc. (Nasdaq: INSM), a developer of follow-on biologics and biopharmaceuticals, today announced that it intends to request a hearing before The NASDAQ Listing Qualifications Panel ('the Panel") to appeal an earlier Staff Determination to delist the Company's common stock from The NASDAQ Capital Market.

Insmed received a letter from The NASDAQ Stock Market ("NASDAQ") on June 17, 2008 indicating that the Company had not regained compliance with NASDAQ's minimum bid price requirement of $1.00 per share for continued listing of Insmed's common stock on The NASDAQ Capital Market as set forth in Marketplace Rule 4310(c)(4) (the "Staff Determination"). As a result, the Company's common stock would be subject to delisting unless Insmed requests a hearing before the Panel. Following procedures set forth in The NASDAQ Marketplace Rule 4800 series; the Company intends to request a hearing before the Panel to review the Staff Determination. The hearing request will stay the delisting of Insmed's common stock, pending the decision of the Panel following the hearing, allowing the Company's common stock to continue to trade on The NASDAQ Capital Market. There can be no assurance, however, that the Panel will grant Insmed's request for continued listing of its common stock on The NASDAQ Capital Market.

In the event that the Panel determines not to grant the Company's request for continued listing of its common stock on The NASDAQ Capital Market, Insmed's common stock may become eligible for quotation and trading on the OTC Bulletin Board.

About Insmed

Insmed Inc. is a biopharmaceutical company with unique protein process development and manufacturing experience and a proprietary protein platform aimed at niche markets with unmet medical needs. For more information, please visit http://www.insmed.com.

Forward-Looking Statements

Th
'/>"/>

SOURCE Insmed Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Insmed Announces First Quarter 2008 Financial Results
2. Insmed to Present at CBI Follow-On Biologics Conference
3. Insmed Selected to Complete Congressional Questionnaire Regarding the Potential Establishment of a Follow-On Biologics Regulatory Pathway
4. Insmed Announces Additional Information in Compliance With NASDAQ Rules
5. Insmed Announces Fourth Quarter and Full-Year 2007 Financial Results
6. Insmed Announces Listing Transfer from Nasdaq Global Market to Nasdaq Capital Market
7. Insmed to Host Fourth Quarter and Full-Year 2007 Conference Call
8. Insmed CEO Issues Statement on White House FY09 Budget and FDA Statements on Follow-On Biologics
9. Insmed President Interviewed for Follow-On Biologics Podcast: Insmed Inc. President Steve Glover Discusses Safe and Effective Biologic Therapies and Reduced Costs with The American Magazine
10. Insmed to Appeal Delisting Notification From Nasdaq
11. Insmed Awarded $2.1 Million by Muscular Dystrophy Association
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... Freeslate, Inc ., the leading ... Lupin Limited, one of India’s top five pharmaceutical companies, ... System for high throughput solid form screening. ... a wide range of quality, affordable generic and branded ...
(Date:1/14/2014)... 14, 2014 Histogen, Inc., a regenerative ... cells grown under simulated embryonic conditions, today announced that ... Suneva Medical, Inc. for physician-dispensed aesthetic products containing Histogen’s ... This agreement is an amendment to the existing license ...
(Date:1/14/2014)... SAN DIEGO and BETHESDA, Md. ... they are joining together with two institutes from the ... more reliable tools for bringing safer, more effective treatments ... with the National Center for Advancing Translational Sciences (NCATS) ...
(Date:1/14/2014)...   Kinaxis ®, provider of RapidResponse ®, a cloud-based ... planning ( S&OP ) service, is proud to be a ... be held at the Hilton San Diego Bayfront, January 30 ... Elisabeth Kaszas , Director of Supply Chain at Amgen, as ...
Breaking Biology Technology:Lupin Selects Freeslate’s CM Protégé PharmD System to Accelerate Polymorph Screening for Drug Development 2Lupin Selects Freeslate’s CM Protégé PharmD System to Accelerate Polymorph Screening for Drug Development 3Histogen and Suneva Medical Expand License for Cell Conditioned Media-based Aesthetic Products Internationally 2Histogen and Suneva Medical Expand License for Cell Conditioned Media-based Aesthetic Products Internationally 3Organovo Announces Collaboration with National Institutes of Health 2Organovo Announces Collaboration with National Institutes of Health 3Event Alert: Kinaxis Customer to Present at the Biomanufacturing Summit "Supply Chain: Improving Network Effectiveness" 2
... Romark Laboratories announced results from its STEALTH C-3 clinical trial, ... genotype 1 chronic hepatitis C.  Study results were presented this afternoon ... American Gastroenterological Association Institute (AGA Institute) during Digestive Disease Week 2010 ... , , ...
... ... on leak testing procedures through the roll-out of a global Summer seminar ... and revolutionise current packaging test methods within the pharmaceutical industry. , ... Belfast (Vocus) May 5, 2010 -- ...
... , NEWTON, Mass. , May 4 Microfluidics International Corporation (OTC ... on Tuesday, May 11, 2010 , at 8:30am ET . , ... (Logo:   http://www.newscom.com/cgi-bin/prnh/20090811/NE59652LOGO ) , ... Michael C. Ferrara , President and Chief Executive Officer, and Peter ...
Cached Biology Technology:Romark Announces Final Data From Clinical Trial of Nitazoxanide in Treatment-Naive Patients With Genotype 1 Chronic Hepatitis C 2Romark Announces Final Data From Clinical Trial of Nitazoxanide in Treatment-Naive Patients With Genotype 1 Chronic Hepatitis C 3Romark Announces Final Data From Clinical Trial of Nitazoxanide in Treatment-Naive Patients With Genotype 1 Chronic Hepatitis C 4Romark Announces Final Data From Clinical Trial of Nitazoxanide in Treatment-Naive Patients With Genotype 1 Chronic Hepatitis C 5Pharmaceutical Leak Testing Practices challenged by SEPHA 2Pharmaceutical Leak Testing Practices challenged by SEPHA 3Microfluidics International Corporation to Report First Quarter 2010 Financial Results on May 11, 2010 2Microfluidics International Corporation to Report First Quarter 2010 Financial Results on May 11, 2010 3
(Date:4/17/2014)... NY, April 17, 2014The development of stem cell therapies ... ability to characterize stem cell populations based on cell ... discovered a new marker that is highly expressed in ... cord blood, which they describe in an article in ... Mary Ann Liebert, Inc., publishers. The article is available ...
(Date:4/17/2014)... consumption advisories for expecting mothers are ineffective in ... organic pollutants (POPs). , The study, performed ... Toronto Scarborough PhD student Matt Binnington and Professor ... environmental contamination, a mother,s compliance with advisories, and ... exposure in her children. , Their model estimates ...
(Date:4/17/2014)... anthrax detection cartridge developed at Sandia National Laboratories and ... easier, faster and cheaper. , Bacillus anthracis ... in soils all over the world and can cause ... animals. The bacteria can survive in harsh conditions for ... may occur through skin contact, inhalation of spores or ...
Breaking Biology News(10 mins):Fish consumption advisories fail to cover all types of contaminants 2Pocket-sized anthrax detector aids global agriculture 2Pocket-sized anthrax detector aids global agriculture 3
... of two species oscillate together (for example, predators and prey), ... A famous example is the Canadian lynx and snowshoe hare, ... But is the opposite also true" If the preys population ... are not tightly linked in the food web" Among ecologists, ...
... experimental model used to simulate astronaut weightlessness in space ... effects of stress on immune organs. Earlier ... the protein osteopontin (OPN) in bone mineral loss associated ... possible by the creation at Rutgers of a mouse ...
... many archaeologists believed to be descended from European wild ... Stone Age farmers, new research suggests. The research ... University, which is published today in the academic journal ... mitochondrial DNA from ancient and modern pig remains. Its ...
Cached Biology News:Hidden interactions between predators and prey: evolution causes cryptic dynamics in ecology 2Mice stressed in simulated weightlessness show organ atrophy 2Mice stressed in simulated weightlessness show organ atrophy 3Pig study sheds new light on the colonisation of Europe by early farmers 2
a1-Antitrypsin (human, alpha-1 AT)...
... vesicles are used to study co-translational ... Processing events such as signal peptide ... glycosylation can be examined by the ... vitro in the presence of these ...
... using Mo Bio luciferase assay. Mo Bio Laboratories ... will allow you to certify your products ATP-Free ... you to deliver them to your customers in ... limit is 3.5 x 10-12 /l, which will ...
... New Concept in Microarrays: Biomedical Photometrics Inc. ... GmbH (Jena, Germany) have collaborated to develop ... ArrayTube System. The DNAscope AT is ... new DNAscope AT automatically reads up to ...
Biology Products: